SEARCH

SEARCH BY CITATION

References

  • 1
    Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries—Key challenges and issues. N Engl J Med 2007;356:190810.
  • 2
    Centers for Disease Control and Prevention. Progress toward implementation of human papillomavirus vaccination—The Americas, 2006–2010. Morb Mortal Wkly Rep 2011;60:13824.
  • 3
    Muñoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)−6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010;102:32539.
  • 4
    World Health Organization. Monitoring the coverage and impact of human papillomavirus vaccine—report of WHO meeting, November 2009. Wkly Epidemiol Rec 2010;85:23743.
  • 5
    Hubbard RA. Human papillomavirus testing methods. Arch Pathol Lab Med 2003;127:9405.
  • 6
    Hariri S, Unger ER, Dunne EF, Swan DC, Patel SS, Sternberg M, Markowitz LE. Prevalence of human papillomavirus (HPV) types detected by digene high-risk and low-risk HPV DNA tests among a nationally representative sample of females in the United States. International Society for Sexually Transmitted Disease Research, 17th Annual Meeting, Seattle, WA, USA, July 2007.
  • 7
    Ermel A, Qadadri B, Morishita A, Miyagawa I, Yamazaki G, Weaver B, Tu W, Tong Y, Randolph M, Cramer H, Brown D. Human papillomavirus detection and typing in thin prep cervical cytologic specimens comparing the digene hybrid capture II assay, the Roche linear array HPV genotyping assay, and the Kurabo GeneSquare microarray assay. J Virol Methods 2010;169:15461.
  • 8
    Stevens MP, Garland SM, Rudland E, Tan J, Quinn MA, Tabrizi SN. Comparison of the digene hybrid capture 2 assay and Roche amplicor and linear array human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J Clin Microbiol 2007;45:21307.
  • 9
    Gravitt PE, Schiffman M, Solomon D, Wheeler CM, Castle PE. A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in the ASCUS-LSIL triage study. Cancer Epidemiol Biomarkers Prev 2008;17:124854.
  • 10
    Wright TC, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol 2012;206:46 e111.
  • 11
    Moyer VA. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;156:88091.
  • 12
    Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008;9:92936.
  • 13
    Gage JC, Ajenifuja KO, Wentzensen N, et al. Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. Int J Cancer 2012;131:29039.
  • 14
    Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003–2004. J Infect Dis 2009;200:105967.
  • 15
    Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, Markowitz LE. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003–2006. J Infect Dis 2011;204:56673.
  • 16
    Dunne EF, Sternberg M, Markowitz LE, McQuillan G, Swan D, Patel S, Unger ER. Human papillomavirus 6, 11, 16, and 18 prevalence among females in the United States—National Health And Nutrition Examination Survey, 2003–2006: opportunity to measure HPV vaccine impact? J Infect Dis 2011;204:5625.
  • 17
    Poljak M, Marin IJ, Seme K, Vince A. Hybrid capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol 2002;25 (Suppl 3):S8997.
  • 18
    Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V. A review of human carcinogens—Part B: biological agents. Lancet Oncol 2009;10:3212.
  • 19
    Peyton CL, Schiffman M, Lorincz AT, et al. Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol 1998;36:324854.
  • 20
    Onyekwuluje JM, Steinau M, Swan DC, Unger ER. A real-time PCR assay for HPV52 detection and viral load quantification. Clin Lab 2012;58:616.
  • 21
    Plummer M, Vaccarella S, Franceschi S. Multiple human papillomavirus infections: the exception or the rule? J Infect Dis 2011;203:8913.
  • 22
    Gage JC, Partridge EE, Rausa A, Gravitt PE, Wacholder S, Schiffman M, Scarinci I, Castle PE. Comparative performance of human papillomavirus DNA testing using novel sample collection methods. J Clin Microbiol 2011;49:41859.
  • 23
    Gravitt PE, Lacey JV, Jr, Brinton LA, et al. Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. Cancer Epidemiol Biomarkers Prev 2001;10:95100.
  • 24
    Datta SD, Koutsky LA, Ratelle S, Unger ER, Shlay J, McClain T, Weaver B, Kerndt P, Zenilman J, Hagensee M, Suhr CJ, Weinstock H. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003–2005. Ann Intern Med 2008;148:493500.